UK Life Sciences Company Directory

TCR bispecific immunotherapies for cancer and infectious disease

Immunocore is a commercial-stage biopharma developing T cell receptor bispecific immunotherapies. Its lead product tebentafusp received FDA approval in 2022 for metastatic uveal melanoma and generated $400 million in revenue in 2025. Three Phase 3 trials are enrolling across melanoma indications, with topline data…

Bispecific TCR therapies targeting HLA-Class II cancer antigens

Yellowstone Biosciences is a pre-clinical biotechnology company developing bispecific T-cell receptor therapies for oncology. The company targets a novel class of HLA Class II antigens expressed across multiple cancers, with an initial programme focused on acute myeloid leukaemia. Its approach is designed to…

Immune cell separation and expansion platform for cell therapies

CoED Biosciences is a biotech developing the Column of Expansion and Differentiation (CoED) platform, a consumable device integrating immune cell separation, functionalisation, and expansion in a single workflow. The system exploits the natural migratory behaviour of immune cells across membranes, replacing…

GMP lentiviral and retroviral vector design and manufacture for CGT

ViroCell Biologics is a specialist contract development and manufacturing organisation providing GMP design and manufacture of lentiviral and retroviral vectors for cell and gene therapy clinical trials. The company serves academic and corporate innovators developing CAR-T therapies, rare disease gene therapies, and…

Cambridge cancer research institute advancing discovery and clinical translation

Cancer Research UK Cambridge Institute is a cancer research institute within the University of Cambridge, investigating tumour biology, early detection and treatment. Its research groups study cancer evolution, genomics and the tumour microenvironment, using imaging and computational approaches to improve diagnosis…

E3 ligase inhibitors stabilising tumour suppressor proteins

Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant proteins. Its proprietary platform has been used to profile over 45 E3 ligases across oncology, cardiovascular, neurological, and autoimmune…

Cancer genetics testing and contract research

Oncologica provides molecular cancer diagnostics and contract research services from its laboratory at Chesterford Research Park near Cambridge. Its Oncofocus testing uses tumour DNA profiling to help clinicians identify potentially relevant targeted treatments and immunotherapies. The company also develops…

Antibody therapeutics targeting glycosphingolipid inflammation

Protalea Bio is a biotech company developing first-in-class therapeutic antibodies to prevent progression from precancerous states to active blood cancers including multiple myeloma and B-cell lymphoma. The company's approach targets glycosphingolipid-related inflammation before disease onset, building on over fifteen…

Cell-free DNA capture reagents for liquid biopsy and cancer diagnostics

BIOCAPTIVA is a biotechnology company developing novel cell-free DNA capture technology to improve liquid biopsy for cancer research and diagnostics. Its proprietary polymer platform captures cfDNA directly from whole blood without centrifuges or additional reagents, delivering substantially higher cfDNA yields than…

G-quadruplex-targeting medicines for precision cancer treatment

Genome Therapeutics is a biotechnology company developing cancer medicines that target G-quadruplex DNA structures associated with tumour biology. Its approach builds on research into non-canonical DNA folding and how these structures influence gene regulation and cancer cell vulnerabilities. The company develops…

CASPAROV AI platform for targets in heterogeneous cancers

Enedra Therapeutics develops targeted cancer medicines designed to address genetic diversity within solid tumours, a major cause of treatment resistance. Its CASPAROV platform combines cancer genomics, AI and functional biology to identify survival mechanisms shared across heterogeneous tumour cells. These convergent…

Biparatopic PD-1/VEGFR2 antibody for solid tumour oncology

Ottimo Pharma is a clinical-stage biotechnology company developing biparatopic antibody therapeutics for solid tumour cancers. Its lead programme, Jankistomig, is a first-in-class single-agent IgG antibody that simultaneously targets PD-1 for immune checkpoint inhibition and VEGFR2 to suppress tumour angiogenesis. The…

Clinical-stage company developing treatments for cancer cachexia and muscle wasting

Actimed Therapeutics is a clinical-stage specialty pharma developing treatments for cancer cachexia and muscle wasting disorders, areas with significant unmet need and no globally approved therapies. Its lead programme has completed Phase 1 and received FDA IND approval, with a Phase 2b/3 trial planned in non-small…

Non-endoscopic molecular diagnostics for early oesophageal cancer detection

Cyted Health is a gastrointestinal molecular diagnostics company developing minimally invasive testing for early detection and monitoring of oesophageal pre-cancer and cancer. Its platform combines a swallowable capsule sponge cell collection device with AI-driven biomarker molecular assays to detect Barrett's…

Precision cancer vaccines to prevent metastatic recurrence

Infinitopes is a clinical-stage biotechnology company developing therapeutic cancer vaccines designed to prevent metastatic recurrence. Its lead candidate ITOP1 is a precision viral vector cancer vaccine targeting tumour antigens in patients with surgically resectable oesophageal adenocarcinoma, to be administered in…

AI platform for bone marrow morphology analysis

Ground Truth Labs is an Oxford-based computational pathology company applying machine learning and computer vision to decode disease in bone marrow tissue. Its platform quantifies morphological markers including fibrosis, blasts, and plasma cells at slide and cell level, and identifies novel prognostic patterns…

ML-driven antibody discovery platform for solid tumour therapeutics

LabGenius Therapeutics is a company developing next-generation therapeutic antibodies using its closed-loop machine learning platform. The platform integrates AI, robotic automation and high-throughput experimentation to co-optimise multispecific antibodies across potency, selectivity and manufacturability…

Global biopharma with UK R&D hub in Hertfordshire

Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a primary hub for early-stage drug discovery, clinical development, computational sciences, and commercial operations. The UK operation contributes…

Global commercialisation of specialty, hospital and rare disease medicines

ADVANZ PHARMA is a global pharmaceutical company focused on the commercialisation of specialty, hospital and rare disease medicines, partnering with biopharma and pharmaceutical development companies to bring treatments to patients. The company's portfolio spans therapeutic areas including hepatology,…

Precision oncology drug discovery via targeted protein degradation

Dark Blue Therapeutics is a precision oncology biotech focused on discovering and developing first-in-class small molecule drugs. The company applies targeted protein degradation to exploit novel cancer vulnerabilities, with a lead programme targeting the MLLT1/3 proteins implicated in acute myeloid leukaemia. Its…